Table 3.

The subgroups analysis for lincRNA-ROR and OS in cancer patients.

					Pooled Data			Test for heterogeneity
Subgroups	Number of Studies	Case (n)	High expression (n)	High expression (%)	HR	95% CI	P-value	P-value	I2 (%)
Univariate analysis
Histological type
Digestive cancer	8	671	294	43.8	2.70	1.85–3.94	<.001	<.001	75.6
Other cancer	5	447	192	43.0	2.12	1.56–2.88	<.001	.996	0.0
Case (n)
< 80	6	275	121	44.0	3.20	2.07–4.95	<.001	.158	37.3
≥ 80	7	843	365	43.3	2.10	1.60–2.74	<.001	.038	54.9
Follow-up (mo)
< 60	4	223	63	28.3	3.35	2.35–4.77	<.001	.555	0.0
≥ 60	9	895	423	47.3	2.21	1.65–2.95	<.001	.010	60.3
Quality
High	11	982	486	49.5	2.33	1.79–3.05	<.001	.006	59.4
Low	2	136	63	46.3	3.64	1.92–6.88	<.001	.289	10.9
Multivariate analysis
Histological type
Digestive cancer	4	394	207	52.5	3.73	1.51–9.22	.004	<.001	87.6
Other cancer	1	229	113	49.3	2.98	1.21–7.37	.018	-	-
Case (n)
< 80	2	139	75	54.0	7.17	4.07–12.65	<.001	.987	0.0
≥ 80	3	484	245	50.6	2.18	1.20–3.98	.011	.067	63.0

CI = confidence interval, HR = hazard ratio, OS = overall survival.